Physician profile
Jia Park
NPI 1588774921
$6,574.45
in general payments reported to CMS, 2019-2025
27 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $548 · 2021: $655 · 2022: $1,096 · 2023: $1,027 · 2024: $1,453 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,138.12 | 2019-2025 | |
| Abbvie INC. | $734.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $645.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $623.71 | 2022-2025 | |
| Lilly USA, LLC | $524.90 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $480.30 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $355.96 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $333.59 | 2022-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $321.42 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $305.62 | 2019-2021 | |
| Pfizer INC. | $277.01 | 2022-2025 | |
| Phadia US INC. | $167.08 | 2019-2024 | Immunocap |
| Xeris Pharmaceuticals, INC. | $145.03 | 2023-2025 | Gvoke Hypopen |
| Insmed, INC. | $81.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.37 | 2024-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $68.00 | 2024-2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $62.78 | 2024 | |
| Esperion Therapeutics, INC. | $56.75 | 2020-2021 | |
| Abbott Laboratories | $40.38 | 2022 | |
| Redhill Biopharma INC. | $21.98 | 2022 | |
| Daiichi Sankyo INC. | $21.23 | 2023 | Injectafer |
| Althera Pharmaceuticals LLC | $20.69 | 2021 | |
| Sanofi Pasteur INC. | $17.59 | 2023 | |
| Exact Sciences Corporation | $17.07 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $16.29 | 2022 | |
| Convatec INC. | $11.54 | 2019 | |
| Allergan, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jia Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.